Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in ...

Petosemtamab (MCLA-158: EGFR x LGR5 Biclonics®): Solid Tumors LiGeR-HN1 phase 3 trial in 1L PD-L1+ r/m head and neck squamous cell carcinoma (HNSCC) and LiGeR-HN2 phase 3 trial in 2/3L r/m HNSCC ...

Piper expects additional Phase II data on the combo in 2025 to “significantly de-risk” the Phase III LiGeR-HN1 study ... 2035 in head and neck squamous cell carcinoma alone.

Utrecht, The Netherlands Thursday, February 20, 2025, 15:00 Hrs [IST] ...

LiGeR-HN1, a phase 3 trial, will evaluate the safety and efficacy ... Merus plans to enroll approximately 500 patients in the trial. Head and neck squamous cell carcinoma (HNSCC) describes a group of ...

r/m head and neck squamous cell carcinoma (HNSCC) and LiGeR-HN2 phase 3 trial in 2/3L r/m HNSCC enrolling – we expect both trials to be substantially enrolled by YE25; clinical update on phase 2 ...

The FDA advances in multiple cancer types, and researchers assess potential impacts of funding freezes on cancer research.

Piper Sandler initiated coverage on Merus N.V. (NASDAQ:MRUS), a $2.8 billion market cap biotech company, with an Overweight rating and a price target of $84.00. According to InvestingPro data, the ...

against six state-of-the-art single cell alignment methods: Seurat v3, BBKNN, Scanorama, Harmony, LIGER, and BERMUDA. Compared to other approaches, CBA preserves the cluster separation in the original ...